doses, as the literature reports them

Before any numbers

This page lists doses, routes, and durations from published research — not guidance for any individual. It answers the question 'what was studied?' not 'what should someone take?' Those are different questions, and for the GLOW blend specifically the second one cannot be answered from the literature because the combination has never been dosed in a controlled human trial. The commercial vial ratio (50 mg GHK-Cu / 10 mg BPC-157 / 10 mg TB-500) is a supplier convention, not a literature-derived figure. What follows is a channel-by-channel account of the doses, species, routes, and durations that actually appear in the published studies cited elsewhere on this site — nothing more, nothing less.

A framing note before any numbers

GLOW is a research-peptide blend. None of its components are FDA-approved for any human therapeutic indication, and the combination has never been studied in humans or animals ^[16]. This page is not a dosing guide. It is a literature summary — a list of the doses, routes, and durations that were actually administered in the published studies cited elsewhere on this site.

That distinction is the entire point. Research-context dose reporting answers the question 'what was studied?' It does not answer 'what should a person take?', because no published research supports that latter question for any of the three components in a human self-administration setting. The numbers below are reported in third person, attributed to specific studies, and bounded by the model the dose was used in (rodent, ex vivo, human pilot, in vitro).

Channel R — GHK-Cu research doses

GHK-Cu research uses three principal dose registers depending on the model.

Topical cosmetic and dermatology studies have generally used GHK-Cu formulations at 0.05% to 0.2% in cream or serum vehicles applied once or twice daily. The 1994 Mulder diabetic-ulcer trial used a 'lamin' GHK-Cu gel applied twice daily for the trial duration ^[1]. The 2025 liposomal formulation literature is exploring whether encapsulation can meaningfully raise transdermal flux at lower concentrations ^[17].

Transcriptomic and cell-biology work has used GHK-Cu in cell culture at 1-10 nanomolar — the concentration range that produced Pickart's roughly thirty-one percent genome-wide expression shift in the Connectivity Map analysis ^[2]. Hair-follicle ex vivo work has used a related AHK-Cu analog at picomolar-to-nanomolar concentrations ^[5].

In vivo rodent fibrosis and lung-injury studies have used GHK-Cu at approximately 3 mg/kg intraperitoneal in multi-day dosing schedules ^[3][4]. These doses are at the higher end of the GHK-Cu literature and reflect the in vivo demands of an inflammatory or fibrotic challenge model rather than a cosmetic context.

Half-life is short — GHK-Cu has a plasma half-life on the order of minutes — but copper-binding affinity prolongs tissue residence. Stability is the formulation-critical variable: oxidation can dissociate the copper-tripeptide chelate, so reconstitution and storage protocols matter.

Channel G — BPC-157 research doses

The most-cited rodent dose across the BPC-157 literature is 10 µg/kg intraperitoneal. This is the dose used in the Achilles tendon transection model ^[7], the Src-Caveolin-1-eNOS vasomotor work ^[8], and most of the gut-protection and brain-gut axis studies summarized by the Sikiric group ^[10]. Oral 10 µg/kg administered via drinking water has also been used in many studies, leveraging BPC-157's notable stability in gastric juice.

Pilot human studies have used different regimens. The McGuire 2025 narrative review notes that the published human pilots used local injection (intra-articular for the knee-pain cohort), intravesical instillation (for interstitial cystitis), or intravenous administration (for the two-patient safety report) ^[9]. Reported local doses ran in the 200-500 µg range, but the dataset is small enough that any 'typical' figure is more anecdote than guideline.

The unpublished Pliva Phase II of BPC-157 (then PL-14736) for ulcerative colitis used a rectal enema with dose escalation ^[16]. Specific dose levels have not been published in a peer-reviewed venue.

Plasma half-life is short — approximately thirty minutes intraperitoneal in rats — but biological effects persist far longer, suggesting downstream signaling cascade activation rather than direct receptor occupancy ^[9].

Channel B — TB-500 research doses

TB-500 — the seventeen-residue fragment of thymosin beta-4 — does not have its own dedicated dose-finding literature. Most of what informs the research-context dose register comes from full-length thymosin beta-4 studies.

Rodent stroke and cardiac models have used full-length Tβ4 at 6 mg/kg intraperitoneal. The 2010 Morris embolic stroke study used 6 mg/kg IP starting twenty-four hours post-stroke, dosed every three days for four total doses ^[14]. The 2004 Bock-Marquette cardiac work used intraperitoneal Tβ4 after coronary ligation; specific mg/kg figures vary across the follow-up literature ^[13].

Ophthalmic trials of RGN-259 (Tβ4) have used a 0.1% topical solution applied multiple times daily for twenty-eight days in the Phase III neurotrophic-keratopathy trial ^[12]. Engineered tandem-Tβ4 corneal work has used topical ophthalmic application in animal models.

Phase I intravenous trials of full-length Tβ4 in human subjects have explored single doses from 42 mg to 1260 mg, with no major safety signal reported at the cited dose levels [from the broader thymosin beta-4 development program, summarized in 11, 12].

Full-length Tβ4 has a plasma half-life of approximately two hours in human trials. The seventeen-residue fragment's pharmacokinetics are not as well characterized in the published literature.

The GLOW combination has no validated dosing

Commercial GLOW vials advertised in research-chemical catalogs typically contain 50 mg GHK-Cu, 10 mg BPC-157, and 10 mg TB-500 per vial. This ratio is vendor convention, not literature-derived ^[16]. No peer-reviewed paper has studied the combination at this or any other ratio.

The gap between component-level evidence and combination dosing is more than a documentation issue. Combination pharmacology can produce dose-response shifts, pharmacokinetic interactions, and emergent toxicities that single-component data does not predict. The absence of GLOW combination studies means there is no published basis for any specific dose, route, schedule, or duration of the three together.

The routes of administration that appear in the per-component literature — intraperitoneal in rodents, topical for GHK-Cu cosmetic work and Tβ4 ophthalmic trials, intra-articular and intravesical in BPC-157 human pilots, oral gavage in BPC-157 rodent gut studies, intravenous in full-length Tβ4 Phase I — are all single-component routes ^[16]. None of them was developed or validated for the three-peptide blend.